The Company Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), is a commercial-stage oncology company and the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer by harnessing the human immune system’s ability to recognize and destroy